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Stroke is a sudden onset neurological deﬁcit due to a cerebrovascular event. In children, the recognition of stroke is often delayed
due to the low incidence of stroke and the lack of speciﬁc assessment measures to this entity. The causes of pediatric stroke are
signiﬁcantlydiﬀerent from that of adult stroke. The lack of safety and eﬃciency data in the treatment is the challenge while facing
children withstroke.Nearly halfofsurvivorsofpediatric strokemayhaveneurologicdeﬁcits aﬀectingfunctionalstatusandquality
of life. They may cause a substantial burden on health care resources. Hence, an accurate history, including onset and duration of
symptoms, risk factors, and a complete investigation, including hematologic, neuroimaging, and metabolic studies is the key to
make a corrective diagnosis.A prompt and optimal treatment without delay may minimize the damage to the brain.
1.Introduction
Stroke is deﬁned as the sudden occlusion or rupture of
cerebral arteries or veins resulting in focal damage and
clinical neurologic deﬁcits. Clinical manifestations of stroke
include weakness or paralysis of a limb, or the sudden
inability to speak, and the onset of the deﬁcit may be
within seconds, minutes, or hours. Stroke is one of the most
common neurological causes for admission to a hospital
and is the second commonest cause of death in the world
[1]. Although stroke is still a disease of the senescence
and the incidence of stroke for old people is approximately
12/1,000, [2–4] stroke in the young people is relatively
rare. The annual incidence rate for stroke in children is 2-
3/100,000 [5]. The incidence of neonatal stroke is much
rarer, approximately 1 in 4000 term live births. There was
a slight female predominance [6–8]. The prevalence of
stroke in the east countries is diﬀerent from that in the
West, and this diﬀerence has been attributed to diﬀerences
in urbanization, change of diet, lifestyles, and healthcare
facilities [9, 10]. Strokeis particularly tragic because ofmuch
longerexpected lifespan ahead leasing to a long-termburden
for the victims, their families, and community, emphasizing
the need for a high degree of clinical suspicion toward
the stroke in the young. The current review focuses on
pediatric strokes.
2.Etiologies
Contrary to adults in whom arteriosclerosis is the leading
cause, risk factors of pediatric strokes are multiple [11],
including cardiac disorders, infection, prothrombotic dis-
orders, moyamoya disease and moyamoya syndrome, and
others.
2.1. Cardiac Disorders. Congenital heart disease (CHD) and
other cardiac problems are still recognized as presumed risk
factors for pediatric stroke [12] .I nt h ep r e s e n c eo fa na t r i a l
or ventricular septal defect with intermittent right-to-left
intracardiac shunting including patent foramen ovale [13–
15], systemic venous clots can reach the cerebral circulation.
In addition, stroke is highly related to procedures such as
surgery of catheterization [12, 16, 17] and Fontan surgery
[18–20]. Prosthetic heart valves are an important source of
emboli [21, 22]. Therefore, most congenital heart lesions
should be repaired to improve cardiac function and reduce
the risk of subsequent stroke. All children with strokes2 Stroke Research and Treatment
of undermined causes should have an echocardiogram
performed.
2.2. Infection. Varicella is reported to be related to pediatric
ischemic strokes [23–27]. Radiographic features of postvari-
cella angiopathy include basal ganglion infarctions and self-
resolving unilateral stenosis of the distal internal carotid or
proximal anterior, middle, or posterior cerebral arteries [28,
29]. Several viruses have been linked to arteriopathies and
strokes in children, but paradoxically, not so many children
have strokes as minor viral infections are so common in
children. It is still not clear how viral infections contribute
to arteriopathies and strokes.
2.3. Prothrombotic and Hematologic Disorders. Inherited
or acquired prothrombotic or coagulation disorders can
predispose children to strokes [30, 31]. Most common
prothrombotic abnormalities include deﬁciencies of protein
C[ 32], protein S [33], antithrombin III [34], plasminogen
[35],anticardiolipin antibody[33],lupusanticoagulant[33],
homocystein [34] and antiphospholipid antibodies [34],
prothrombin 20210A gene [36], and mutated Factor V [37]
and mutated methyl-tetrahydrofolate reductase (MTHFR)
[38]. Coagulation studies should be performed in any child
with stroke without identiﬁed risk factors. Abnormal results
on samples taken within several weeks of the stroke should
be conﬁrmed by testing parents, if the abnormality is a
hereditary coagulation abnormality, or the child should be
retested several months later.
2.4. Moyamoya Disease and Moyamoya Syndrome. Moy-
amoyadiseaseisanonatherosclerotic,noninﬂammatory, and
nonamyloid vasculopathy characterized by chronic progres-
sive stenosis or occlusion of the terminal internal carotid
arteries and/or the proximal portion of the anterior cerebral
arteries and/or middle cerebral arteries [39]. Moyamoya
disease is more common in girls [40]a n dp e a k si nb o t h
the ﬁrst and fourth decades of life [41]. The deﬁnitive
method for diagnosis is conventional angiography, which
may show a pattern of “hazy, cloudy puﬀ of smoke.” The
underlying reﬂects an abnormal network of small collateral
vessels in response to the stenosis (Figure 3). In Japanese, the
term“moyamoya” represents theappearance ofradiographic
features [42]. The clinical course may be stable, may appear
recurrent transient ischemic attacks (TIAs), and may mani-
fest strokes with progressive neurologic impairment or alter-
nate hemiplegia [43, 44]. Partial and secondary generalized
seizures are common in younger children [45]. No speciﬁc
medical therapy can eﬀectively halt the progression of moy-
amoya disease. Complications of moyamoya disease include
intellectual impairment and permanent motor deﬁcits [46].
The moyamoya syndrome shows radiographic features of
moyamoya disease but diﬀerent underlying etiologies, such
as sickle cell disease or postradiation vasculopathy. Revascu-
larization including anastomosis of the superﬁcial temporal
artery to the cerebral artery, encephalomyosynangiosis, and
encephaloduroarteriosynangiosis [47]i sp r o m i s i n gb e c a u s e
it is associated with a reduced stroke rate [48].
2.5. Other Risk Factors. Hyperlipidemia is one of the most
common risk factors for stroke in a Chinese young stroke
study [49]. Mild trauma or exertion causing cerebral arterial
dissection may lead to pediatric stroke [8]. Hsu et al.
[50] reported a child suddenly experienced left hemi-
paralysis after performing repeated backward somersault
resulting in an isolated middle cerebral artery dissection
(Figure 4). When the dissection of carotid or vertebral
arteries occurs, this event may result from a tear to the
arterial wall often related to trauma. However, this tragedy
may occur spontaneously in children [51]o rb ec a u s e d
by nonaccidental traumas and strangulation. If there is
any unexplained subdural hemorrhage (SDH) in infants
(Figure 2), nonaccidentaltraumas should be considered,and
retinal hemorrhage may provide a supportive clue of shaken
baby syndrome. Migraine is also a dangerous risk factor
because literature shows that women who had experienced
onset of migraine within the previous year had 6.9-fold
higher odds of stroke compared with women without a
history of migraine [52]. Vasculitis, such as polyarteritis
nodosa [53], Takayasu’s arteritis [54], mixed connective
tissue disease [55], and systemic lupus erythematosus [56],
has all been reported in childhood strokes. An elevated
homocystein level appears to be associated with strokes in
young Asian patients [57]. Patients with Fabry’s disease,
a lack of alpha galactosidase, may have multiple lacunar
cerebral infarcts in aﬀected boysduring the teenageand early
adult years [58]. Mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes (MELAS syndrome)
in children present with episodes of nausea, vomiting,
headache, seizures, hemiparesis, and cortical blindness.
Infarct-like lesions in the cerebral cortex, basal ganglia, and
brainstem are conﬁrmedbyautopsy[59].Cranial CTorMRI
shows areas of infarctions that do not correspond to major
vascular distributions. A3243G mutation aﬀecting the rates
of mitochondrial translation and respiration consequently
causes the mitochondrial dysfunction [60]. Children with
neuroﬁbromatosismayhavecomplicationsofcerebralarteri-
opathies [61]. History of use of oral contraceptives and illicit
drugs (amphetamines, cocaine) is a risk factor for strokes in
the young people.
3.ClinicalFeatures
Seizures, irritability, or altered consciousness are common
in infants and young children, but hemiparesis is diﬃcult
to recognize in this age group [11]. Older children typically
present with speech, visual, focal sensory, or coordination
abnormalities. Dystonia is more common in children with
basal ganglia infarction than in adults. TIAs are increasingly
recognized in children and infants [11]. Even so, the rec-
ognition of cerebral infarction in children is often delayed
due to the low incidence of stroke and the lack of awareness
of pediatricians to this entity [62]. Hence, clinical features
obtained from the history and physical examination can
provide signiﬁcant information. For instance, a recent head
orneckinjurysuggestsdissection.Arecentvaricellainfection
should lead to consideration of postvaricella angiopathy.Stroke Research and Treatment 3
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Figure 1: A 17-year-old boy was presented with seizures one month after a prior head injury. Axial T1-weighted image (a) and coronal
T2-weighted image (b) showed the hemosiderin deposition and a small CSF-ﬁlled cavity of the left middle frontal gyrus.
(a) (b) (c)
Figure 2: A 4-month-old infant was presented with a large head circumference followed by seizure-like episodes. Axial T2-weighted image
(a) showed hydrocephalus and prominent CSF space along bilateral cerebral convexities. The ﬂuid was subdural hematomas because the
signal intensity of the ﬂuid is diﬀerent from that of CSF on FLAIR T2-weighted image (b). Coronal T2-weighted image showed hypoplasia
of the left hippocampus.
Migraine and oral contraceptive, amphetamine, or cocaine
use all predispose to infarction. A family history of stroke
[63], heart attack, lipid problems, and calf deep vein or
pulmonary thrombosis at young ages may be associated
with increased stroke risk. Physical examination such as
head or neck bruits, cardiac murmurs or skin lesions of
tuberous sclerosis, Neuroﬁbromatosis or Fabry’s disease may
also provide additional clues.
4.Classiﬁcation
Strokes can be subdivided into two types: ischemic and
hemorrhagic.
4.1. Hemorrhagic Stroke. Hemorrhagic stroke is as common
as ischemic stroke in childhood, and nearly half of pediatric
strokes are hemorrhagic [64]. There are two major types
of hemorrhagic stroke which reﬂect the anatomic site of
the bleeding and are classiﬁed as “intracerebral hemorrhage
(ICH)” and “subarachnoid hemorrhage (SAH).” They can
coexist in individual patients, such as when rupture of an
arteriovenous malformation (AVM) producesboth SAHand
ICH. In contrast to ischemic stroke, deﬁnitive treatment
for hemorrhagic stroke frequently requires neurological
intervention [65, 66].
4.2. Intracerebral Hemorrhage (ICH). ICH devastates chil-
dren with death reported in up to 33% and permanent
deﬁcits in up to 40%, including seizures and cognitive
and motor impairment [65, 67]. ICHs result from the
rupture of cranial vessels and are classiﬁed as extradural,
subdural, subarachnoid, intracerebral, or intraventricular.
Compared with adults, pediatric ICH is more likely to
result from a bleeding diathesis due to inherited hemophilic
or thrombocytopenic disorders [68]. In acquired condi-
tions, ICH is present in at least 9% of infants undergo-
ing extracorporeal membrane oxygenator (ECHO) proce-
dure and occurs early after initiation of bypass in 85%
[69]. Trauma is the common cause for ICH in children
(Figure 1). Typical clinical features in children are seizures,4 Stroke Research and Treatment
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Figure 3: A 17-year-old boy was presented with sudden loss of consciousness and generalized seizure attack. Nonenhanced CT study (a)
showed acute intraventricular hemorrhage. CT angiography (b, c) disclosed occlusion of bilateral prebifurcation M1 segment of middle
cerebral arteries with some moyamoya vessels (arrows).
(a) (b) (c)
Figure 4:A15-year-old boysuddenlyexperienced acute right-sided headache anddizzinessfollowedby drowsyconsciousnessandleft-sided
weakness after practicing backward somersaults. Nonenhanced CT image of the brain (a) showed increased attenuation at the M1 segment
ofthe right MCA(white arrowhead). Apparent diﬀusionmapofthebrain(b)delineated a2.4-cmlow-signalarea intheposteriorlimbofthe
right internal capsule, consistent with a hyperacute infarct (arrow). Magnetic resonance angiography of the brain (c) showed focal stenosis
of the right MCA with decreased ﬂow and number of distal branches (white arrowhead).
decreasing levelsof consciousness, and IICP. It is unusual for
infants to present bulging fontanel and splayed sutures and
focal signs resulting from the increasing volume of intracra-
nial blood, edema, or secondary hydrocephalus because
infants with nonfused cranial sutures can accommodate to
increase in brain volumes with raised ICP. The periven-
tricular germinal matrix of preterm neonates is extremely
vulnerable to hypoxia. Once hemorrhage occurs, blood may
extend into the ventricular system and cause extension of
hemorrhage because the unmyelinated brain of infant oﬀers
relatively less mechanical resistance than the adult brain.
Available evidence shows that pediatric ICH is caused by
hematologic abnormalities and infratentorial hemorrhage
location [70], and ICH volume [71] is associated with poor
outcome.
4.3. Subarachnoid Hemorrhage (SAH). SAH is a neurologic
emergency characterized by the extravasation of blood into
the spaces covering the CNS that are ﬁlled with CSF [72].
Ruptures of aneurysms, AVMs, and head trauma are the
major causes for SAH. The underlying cause for neonate
SAH is usually hypoxia in preterm or trauma in term
infants. Trauma is the common cause for SAH in children
[73]. Rupture of an aneurysm accounts for 80% of cases
[74]. In infants, most aneurysms tend to rupture less
than 2 years of age or in children older than 10 years
[75]. Typical presentations of SAH include a sudden and
severe onset of headache, a stiﬀ or painful neck, vision
loss, inability to move an arm or leg, numbness, speech
diﬃculty, and/or loss of consciousness in adults, and there
may be intermittent seizures or no symptoms on a well baby.
SAH is occasionally detected on CT, MRI, or postmortem
in neonates after a normal or minor traumatic vaginal
delivery. Lumbar puncture should be performed in any
patient with suspected SAH and equivocal results on head
CT scanning. MRI and MRA can provide good visualization
of aneurysms, but angiography is more reliable. Treat-
ment of patients with aneurysmal SAH not only involves
securing the aneurysm by endovascular coiling or surgical
clipping but also prevention and treatment of the medi-
cal and neurological complications, including symptomatic
vasospasm [76], hydrocephalus [77], and rebleeding [78].
More than half of survivors report problems with memory,
mood, or neuropsychological function [72]. The averageStroke Research and Treatment 5
case mortality rate for SAH is 51% [79]. Early identiﬁcation
and therapy of cerebral and systemic complications are
very important to preserve and improve functional out-
come.
4.4. Cerebral Sinovenous Thrombosis (CSVT). CSVT is de-
ﬁ n e db yt h ep r e s e n c eo ft h r o m b u so rﬂ o wi n t e r r u p t i o n
within cerebral veins or dural venous sinuses. More rapid
rates of occlusion of cerebral venous structures lead to a
rise in cerebral venous pressure that are more likely to
produce infarction and occasionally may interfere regional
perfusion. CVST is rare in children and the incidence is
0.67 per 100,000 children per year with over 40% occurring
in newborn [80]. CSVT has been reported in neonates
with asphyxia, lethargy, jitteriness, and seizure without focal
signs [80–83] and in 25% of children with pseudotumor
cerebri [84]. Iron-deﬁciency anemia has been increasingly
reported in pediatric patients with CSVT [85–87]. In septic
CSVT, a bacterial infection adjacent to the sinuses spreads
directly into the sinus, provoking thrombophlebitis. Dehy-
dration is a dangerous signal for SVT because of increased
hemoconcentration impairing laminar ﬂow. In neonates,
the increased risk for CSVT may be due to the location
of the major dural sinuses along the bony suture lines
and their consequent mechanical distortion during calvarial
molding in the birth process [88]. In older children, head
trauma or cranial surgery may damage the dural sinuses,
leading to CVST [89, 90]. The diagnosis of CVST requires
neuroimaging evidence of thrombus or lack of ﬂow in the
cerebral veins or venous sinus. However, brain CT scan
may yield false-positive results, particularly in neonates.
Spiral CT imaging can delineate vascular ﬂow, enabling
noninvasive cerebral CT venography [91]. MRI can clearly
visualize bothabsent ﬂow and the presence ofthrombus, clot
progression, and resolution over time as well as associated
parenchymal lesions have made MRI the diagnostic study of
choice in CSVT [84, 92, 93]. Cerebral angiography is still the
gold standard especially when CT or MRI is not deﬁnitive.
Treatment of SVT includes general supportive measures and
antithrombotic and nonantithrombotic therapies. Studies
showed that anticoagulants were used in up to 50% of
childhood CSVT patients without signiﬁcant hemorrhagic
complications [80, 94]. For neonates with CSVT, unfrac-
tionated heparin or low-molecular-weight heparin given
for 7 days followed by low-molecular-weight heparin alone
for 6 to 12 weeks is indicative. For older infants and
children, unfractionated heparin or low-molecular-weight
heparin given for 7 days, followed by Coumadin for 3 to 6
months,isatreatment option.Ifsigniﬁcant ICHisassociated
with SVT, the use of anticoagulants is controversial. Septic
SVT requires antibiotics and may need surgical removal
and drainage of the infection. Regular cranial ultrasound
can monitor and screen the course of CSVT. The long-
term outcome in adults with SVT is quite good, but
mortality rate in pediatric CSVT is reported to be 6 to 30%
[95, 96]. Therefore, children with CSVT should be closely
monitored.
5.Diagnosis
The diagnosis of stroke relies mainly on a detailed history,
careful neurological examination and astute suspicion, and
its diﬀerentiation from other conditions that mimic stroke’s
presentations. The conﬁrmation requires laboratory inves-
tigations including (1) a full blood count (CBC) to detect
polycythemia,thrombocytosis,oranemia;(2)ESRtoexclude
arteritis or bacterial endocarditis; (3) levels of urea and elec-
trolytes to reveal any electrolyte disturbance that can mimic
stroke; (4) level of blood glucose; hyper-and hypoglycemia
can mimic stroke, and diabetes mellitus is a risk factor;
(5) serum cholesterol; a well-known risk factor for strokes
and heart attack; (6) syphilis serology as syphilis is a rare
but treatable cause of stroke; (7) blood cultures should be
performed if there is any suspicion of bacterial endocarditis.
EKG may detect cardiac sources of ventricular hypertrophy
and/or arrhythmia. Chest X-ray can demonstrate cardiac
sources of emboli, ventricular hypertrophy, and/or any
organic lesions. Doppler ultrasound can detect large vessel
vasculopathy in carotid and intracranial arteries. CT scans,
CT spiral angiography, and MRI may navigate clinicians
the anatomy of each major artery in the brain and localize
hemorrhages and damaged tissue. MRI is far superior to
CT in detecting small and multiple infarcts, especially in
the brainstem and cerebellum. Modiﬁcations ofMRI include
diﬀusion-weighted imaging, perfusion MR imaging, proton
spectroscopic imaging, and MRA, that have improved the
early detection and speciﬁcity of ischemic injury. Moreover,
single-photon emission computed tomography (SPECT)
scanning can detect areas of hypoperfusion that may occur
earlier than other radiographically detected defects in the
arterial ischemic stroke.
6.Treatment
In acute stage, newborns with arterial ischemic stroke
rarely require antithrombotic treatment; children with stroke
should be stabilized promptly and transferred to a tertiary
care centers with expertise that can provide specialized
pediatric neurovascular care, because their autoregulation
of CNS vascular system is dysfunction [97]. Optimal treat-
ment, including antithrombotic therapies, thrombolytics
agents, neuroprotective agents, neurosurgical procedures,
and careful monitor of blood pressure, body temperature,
and biochemical data such as hemoglobin and blood glucose
and careful ﬂuid management, should be given to minimize
the damage to the brain.
6.1. Heparin. Heparin, a large heterogenous polysaccharide
complex, cannot cross the placenta. The mechanisms of
Heparin are those that enhance the rate by which antithrom-
bin III neutralizes the activity of several activated clotting
proteins, especially factor Xa and thrombin in turn prevent
clot extension or new clot formation [98]. The average t1/2
of intravenous heparin is about 60 minutes in adults and
c a nb ea ss h o r ta s3 0m i n u t e si nt h en e w b o r n .H e p a r i n
is commonly used in children for deep vein thrombosis
and pulmonary embolism. Heparin has been the standard6 Stroke Research and Treatment
therapy for acute anticoagulation following stroke [99].
Heparin is given at maintenance dose of 28units/kg/hour
in infants, 20units/kg/hour in children older than 1 year
of age, and 18units/kg/hour in older children. The target
activated partial thromboplastin time is 60 to 85 seconds or
1.5 to 2 times of the baseline value. A recent central nervous
system hemorrhage; bleeding from inaccessible sites; malig-
nant hypertension; bacterial endocarditis; recent surgery of
the eye, brain, or spinal cord; current administration of
regional or lumbar block anesthesia are contraindicated in
the anticoagulationtreatment with heparin. Because heparin
can be neutralized by protamine sulfate, speciﬁc heparin
levels should be obtained so that the heparin level is 0.35–
0.70Unit/mL by antifactor Xa assay or 0.2–0.4unit/mL
by protamine sulfate assay. Low-molecular-weight (LMW)
heparin has become the ﬁrst choice foracute anticoagulation
therapy because adults with arterial infarcts treated with
low-molecular-weight (LMW) heparin may have a better
outcome [100] and so as to that in children [101]. However,
adultpatientsreceiving LMWheparin usually do notneed to
havetheirheparinlevelsmonitored,butinpediatricpatients,
monitoring is critical to ensure that a therapeutic level is
achieved, which for antifactor Xa is 0.5 to 1.0units/mL
in a sample drawn 4 to 6 hours after the subcutaneous
dose.
6.2. Warfarin. Warfarin is an oral anticoagulant drug that
reduce the activity of the vitamin K-dependent coagulation
factors: II, VII, IX, and X, as well as protein C and
protein S. Prothrombin time (PT) is the clotting test used
to assess warfarin anticoagulation. Warfarin is used in
adults for the secondary prevention of stroke in situations
in which aspirin therapy has failed. In children with
cerebrovascular disorders, including severe hypercoagulable
states, arterial dissection [102], cardiogenic embolism [102],
cerebral sinovenous thrombosis (CSVT) [103], and ischemic
stroke or TIA [104], the international normalized ratio
(INR) for standard treatment of thrombosis is 2.0-3.0.
The most serious side eﬀect of warfarin is hemorrhage.
Contraindications to Warfarin anticoagulants are essentially
the same as those for heparin therapy.
6.3. Thrombolytic Agents. Thrombolytic agents include
streptokinase, urokinase, prourokinase, and recombinant
tissue-type plasminogen activator (rTPA). Natural streptoki-
nase is isolated and puriﬁed from streptococci. Streptokinase
is not a protease and has no enzymatic activity; however,
it forms a complex with plasminogen that releases plasmin
[105]. Urokinase is occasionally referred to as urinary-
type plasminogen activator (uPA) because it is formed by
kidneys and is found in urine [106]. One beneﬁt over
streptokinase is that urokinase is nonantigenic; however,
this is oﬀset by a much greater cost. Lack of ﬁbrin
speciﬁcity makes streptokinase and urokinase less desirable
thrombolytic drugs than rTPA compounds. Single-chain
urokinase-type plasminogen activator or prourokinase is
a zymogen with an intrinsic catalytic activity which is
greater than that of most of the other zymogens. Intra-
arterial prourokinase administration has been proved to be
beneﬁcial in clinical trails in adults within 6 hours of the
onset of acute ischemic stroke caused by MCA occlusion
which signiﬁcantly improved clinical outcome at 90 days
[107], and the risk of symptomatic intracranial hemorrhage
was increased in the presence of acute hyperglycemia [108].
rTPA is a puriﬁed glycoprotein produced by recombinant
DNA technology. It has the property of ﬁbrin-enhanced
conversion of plasminogen to plasmin and is successfully
used in acute myocardial infarction [109] and ischemic
stroke [110]. Although studies show that the intravenous
rTPA administration is eﬀective in reducing disability and
possibly decreasing the size of the infarct [110, 111], many
patients are left with moderate to severe neurological deﬁcits
in this manner. Intra-arterial treatment is proposed for its
higher rates of recanalization, lower doses of thrombolytics
used compared with intravenous therapy, and lower rates of
intracerebral hemorrhage (ICH) [112, 113]. However, the
US Food and Drug Administration only approves the use
of intravenous rTPA in adults with acute ischemic stroke,
and the condition for this thrombolytic agent is that the
durationbetweenonsetofsymptomsandthetimefortheuse
ofrTPAiswithinthreehoursandcanbeextendedtofourand
half hours in certain patients [114]. Clinical trials evaluating
the feasibility and eﬃcacy of intravenous and intra-arterial
rTPA therapy for pediatric strokes are diﬃcult because of
the frequent delay in diagnosis and the lack of safety data. A
study onthesafetyand eﬀectivenessofalowdoseofrTPA for
thrombolysis in children with arterial and venous thrombi is
under investigation and the results are promising [115].
6.4. NeuroprotectiveAgents. Accumulativeevidencesupports
that hypothermia can protect against brain damage, espe-
cially in neonates with hypoxic ischemic encephalopathy
[116, 117]. Hypothermiainadultswithstrokemaybe associ-
ated with serious sequelae, such as hypotension, arrhythmia,
and pneumonia [118]. Early use of antiepileptic drugs in
childrenwithseizuresassociatedwitharterialischemicstroke
is essential to prevention from recurrent seizures that may
worsen the infarct volume [119].
6.5. Neurosurgical Procedures. Emergent decompression
with hemicraniectomy may save a patient’s life when a huge
amount of hemorrhage and/or hematoma causes herniation.
6.6. Rehabilitation Therapy. Compared with old patients
with strokes, infant and young children have additional
rehabilitation diﬃculties, including feeding dysfunction
relatedtospeechtherapyandongoingmodiﬁcationtherapies
when they grow and develop age-related skills over time.
Hemiatrophy limbs can cause orthopedic problems, such as
leg length discrepancy. Moreover, these patients may develop
learning and behavior problems and require intervention by
specialized pediatric rehabilitation and education teams. It is
necessary toencouragepatients’ families and remind themof
avoiding overprotection. What is more important is to treat
the aﬀected child as normally as possible.Stroke Research and Treatment 7
7.Conclusion
With half of the world’s population, stroke in Asia is
important globally. With an aging population, there is an
expected rise in numbers of stroke and a corresponding
increase in the burden of stroke in Asia. Indeed, tremendous
eﬀorts have been made to increase public recognition of
adult stroke, and similarly most of the studies have been
directed to understanding and evaluating prevention and
treatment strategies in adult stroke. In fact, there are
importantdiﬀerencesbetweenadultandpediatricstrokethat
limit the applicability of data from adult research to this
population. Therefore, multicenter collaborative databases
are needed to have a global view on the causes, treatment
approaches, and outcome of the stroke in the young people.
In fact, strokes in the young still remain less noticeable
even among clinicians. Given the far better potential for
outcome and longer duration of disability in children with
stroke compared with adults, further studies are needed to
reﬁne our understanding of underlying mechanisms and
improve the development of rational therapies for pediatric
stroke.
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